Foundation Medicine & European Organisation for Research & Treatment of Cancer (EORTC) Announce Collaboration to Advance Prec...
January 30 2018 - 7:00AM
Business Wire
Foundation Medicine, Inc. (NASDAQ:FMI) and the European
Organisation for Research and Treatment of Cancer (EORTC) announced
today a collaboration in which Foundation Medicine’s comprehensive
genomic profiling (CGP) tests will be used to inform patient
eligibility for oncology clinical trials through the EORTC’s
Screening Patients for Efficient Clinical Trial Access (SPECTA)
program. SPECTA is a pan-European network built by the EORTC with
key institutions collaborating to provide efficient access for
patients to molecularly driven clinical trials.
“Oncology clinical trials are essential to advancing research
and drug development while enabling patient access to potential
clinical treatment options. Yet, currently only a small fraction of
cancer patients enroll in clinical trials,” said Vincent Miller,
M.D., chief medical officer at Foundation Medicine. “The EORTC is a
renowned leader in integrated translational research, and their
SPECTA program is an exciting opportunity for oncologists to
utilize our robust genomic profiling tests to more efficiently
match patients with appropriate clinical trials. Together,
Foundation Medicine and the EORTC can work toward improved access
to innovative clinical trials, helping to accelerate precision
oncology for more patients.”
The collaboration brings together the EORTC, an independent,
non-profit clinical research organization in cancer, and Foundation
Medicine, a leader in molecular information that offers a suite of
CGP assays that identifies the molecular alterations in an
individual’s cancer to inform precision medicine treatment
approaches.
“SPECTA serves as a shared and integrated translational and
clinical research infrastructure for knowledge development and
ultimately allows matching patients to clinical trials based on
both their clinical characteristics and the molecular profiles of
their tumors,” said Denis Lacombe, M.D., EORTC Director General.
“Our collaboration with Foundation Medicine will provide access to
innovative, biomarker-driven clinical trials that will ultimately
usher in a new era of targeted therapy in oncology.”
Under the agreement, Foundation Medicine will provide genomic
testing services for the SPECTA program through three of its
genomic profiling assays: FoundationOne®, its flagship assay for
solid tumor cancers that includes analysis of genomic biomarkers
such as microsatellite instability (MSI) and tumor mutational
burden (TMB), FoundationOne®Heme, an assay for hematologic
malignancies and sarcomas that also includes MSI analysis, and
FoundationACT®, a liquid biopsy assay for solid tumors. Genomic
profiling results will help inform patient eligibility and
facilitate enrollment in clinical trials. Samples will be processed
at any one of Foundation Medicine’s laboratories located in the
United States and Europe.
About EORTCThe European Organisation for Research and
Treatment of Cancer (EORTC) brings together European cancer
clinical research experts from all disciplines for trans-national
collaboration. Both multinational and multidisciplinary, the
EORTC Network comprises more than 4000 collaborators from all
disciplines involved in cancer treatment and research in more than
800 hospitals and institutions in over 35 countries.
Through translational and clinical research, the EORTC offers an
integrated approach to drug development, drug evaluation programmes
and medical practices. EORTC Headquarters, a unique pan-European
clinical research infrastructure, is based in Brussels, Belgium,
from where its various activities are coordinated and run.
About Foundation MedicineFoundation Medicine (NASDAQ:FMI)
is a molecular information company dedicated to a transformation in
cancer care in which treatment is informed by a deep understanding
of the genomic changes that contribute to each patient's unique
cancer. The company offers a full suite of comprehensive genomic
profiling assays to identify the molecular alterations in a
patient's cancer and match them with relevant targeted therapies,
immunotherapies and clinical trials. Foundation Medicine’s
molecular information platform aims to improve day-to-day care for
patients by serving the needs of clinicians, academic researchers
and drug developers to help advance the science of molecular
medicine in cancer. For more information, please visit
http://www.FoundationMedicine.com or follow Foundation Medicine on
Twitter (@FoundationATCG).
Foundation Medicine®, FoundationOne®, FoundationOne®Heme and
FoundationACT® are registered trademarks of Foundation Medicine,
Inc.
Cautionary Note Regarding Forward-Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the value and
performance capabilities of Foundation Medicine’s comprehensive
genomic profiling (CGP) assays; the ability of Foundation
Medicine’s CGP assays to identify patients eligible to participate
in specific clinical trials, help improve efficiencies, and
streamline clinical trial enrollment; and the ability of a clinical
trial to accelerate precision oncology, expand access to therapies,
or improve cancer care. All such forward-looking statements are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include the risk that Foundation Medicine’s CGP
assays and services will not be able to identify genomic
alterations in the same manner as prior clinical data or prior
experience; clinical trial enrollment does not become more
efficient or increase in the expected manner; and the risks
described under the caption “Risk Factors” in Foundation Medicine’s
Annual Report on Form 10-K for the year ended December 31, 2016,
which is on file with the Securities and Exchange Commission, as
well as other risks detailed in Foundation Medicine's subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and Foundation Medicine undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180130005042/en/
Foundation Medicine, Inc.Media Contact:Lee-Ann Murphy,
617-245-3077pr@foundationmedicine.comorInvestor
Contact:Kimberly Brown,
617-418-2215ir@foundationmedicine.comorDavi Kaur, +32 2774
1513communication@eortc.be
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Jul 2023 to Jul 2024